Skip to content

The Effects of ProFoveate on Reducing Self-Stimulating Behaviors

The Effects of ProFoveate on Reducing Self-Stimulating Behaviors in Children Diagnosed With Autism Spectrum Disorders

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02088047
Enrollment
4
Registered
2014-03-14
Start date
2014-08-30
Completion date
2018-10-04
Last updated
2020-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorders, Exhibit Self- Stimulating or Ritualistic Behaviors, Normal Hearing, Normal Intelligence

Keywords

Autism, Self-Stimulating behaviors, Autism Spectrum Disorders

Brief summary

This study is designed to pilot an intervention technique to reduce the self-stimulating behaviors seen in individuals with autism spectrum disorders using intervention with ProFoveate pellets. Self-stimulating behaviors like hand flapping, eye blinking, and rocking, can interfere with the individual's ability to interact with their peers. Participants will wear the pellets for four week and measures with taken again. Another group of participants will not get the pellets. Both groups will be tested at the beginning and end of the study. Any variations in self-stimulating behaviors will be documented through parent report, Observational data. The investigators hypothesize that they will see changes in self- stimulating behaviors as a result of the strategic placement of the ProFoveate™ pellets on the ears of one group of the participants.

Interventions

DEVICEProFoveate

ProFoveate™ intervention for nystagmus is a management approach comprised of non-magnetic, 1.2 mm spheres that can be made from either stainless steel, gold plated stainless steel or titanium, placed strategically about the face and ears and a set of exercises designed to support improved vision for patients with nystagmus.The spheres (i.e., stimulating press balls or pellets) are supplied in packages of 20 with each sphere supplied on a transparent hypoallergenic adhesive tape approximately 7.6 mm in diameter. Within each package, all spheres are individually contained on a single paper backing measuring approximately 8.5 cm by 1.7 cm. Individual pellets (with adhesive tape) are removed from the backing as needed according to the prescribed treatment regimen.

Sponsors

University of Arkansas
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
10 Years to 17 Years
Healthy volunteers
Yes

Inclusion criteria

* Have a documented diagnosis of high functioning autism spectrum disorders (autism, Asperger's syndrome, or Pervasive Development Disorder (PDD) as reported by specialists who use the established criteria (American Psychiatric Association,2000) * Pass a hearing screening at 25 decibels for the frequencies 1000, 2000 and 4000 hertz * Score 85 or above on the Test of Nonverbal Intelligence- 4 (TONI-4; Brown, Sherbenou & Johnsen, 2009) * Exhibit noticeable self- stimulating or ritualistic behaviors (i.e., scratching, hand flapping, eye blinks, etc.) and/or visual characteristics of Autism Spectrum Disorder (ASD) (sensitivity to light, visual fixations, poor eye contact, etc.) as reported by parents and/or observed on videos taken during assessment.

Exclusion criteria

* Known history of latex allergy * Intelligence Score below 85 * Fail the hearing screening

Design outcomes

Primary

MeasureTime frameDescription
Numbers of Self-stimulating BehaviorsBaseline to 4 WeeksOnly 4 participants completed enrollment.Only 3 participants completed study. Study was terminated due to low enrollment.

Countries

United States

Participant flow

Participants by arm

ArmCount
Profoveate
The experimental group will receive the ProFoveate™ intervention along with pre (baseline) and post (end line)intervention assessment.
3
NonProFoveate
Participants in the control group will have no intervention. They will receive the initial pre testing (baseline) followed by post testing after 4 weeks.
1
Total4

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyWithdrawal by Subject10

Baseline characteristics

CharacteristicProfoveateNonProFoveateTotal
Age, Categorical
<=18 years
3 Participants1 Participants4 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants1 Participants1 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
3 Participants0 Participants3 Participants
Sex: Female, Male
Female
3 Participants0 Participants3 Participants
Sex: Female, Male
Male
0 Participants1 Participants1 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 20 / 1
other
Total, other adverse events
0 / 20 / 1
serious
Total, serious adverse events
0 / 20 / 1

Outcome results

Primary

Numbers of Self-stimulating Behaviors

Only 4 participants completed enrollment.Only 3 participants completed study. Study was terminated due to low enrollment.

Time frame: Baseline to 4 Weeks

Population: Students were given a Social Skills Improvement System (SSiS). Only 4 participants completed enrollment. Only 3 participants completed study. Study was terminated due to low enrollment.

ArmMeasureValue (MEAN)Dispersion
ProfoveateNumbers of Self-stimulating Behaviors40 behaviorsStandard Deviation 7.24
NonProFoveateNumbers of Self-stimulating Behaviors27 behaviorsStandard Deviation 1.6

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026